Moxifloxacino Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin works by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for DNA replication and transcription. This dual inhibition prevents bacterial DNA synthesis, leading to bacterial cell death and eradication of the infection.

The dosage and duration of therapy are determined by the prescribing clinician based on the type and severity of the infection, patient weight, renal and hepatic function, and local antimicrobial guidelines. No fixed regimen is provided here.

Moxifloxacino Kabi is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It should be used only when the potential benefit justifies the potential risk. Limited data are available for breastfeeding; a risk‑benefit assessment is required.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive and atypical pathogens compared with older fluoroquinolones such as ciprofloxacin. It also has a longer half‑life, allowing once‑daily dosing in many regimens, but shares class‑related risks like tendon toxicity and QT prolongation, which must be weighed against therapeutic benefits.

The product must be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. During handling, keep the vial in its original packaging, use aseptic technique for preparation, and discard any solution that appears discolored or particulate.

Moxifloxacino Kabi is given by intravenous infusion. The preparation is diluted in an appropriate compatible solution and infused over the period recommended by the prescribing clinician, typically over 60 minutes, using sterile technique and appropriate infusion equipment.

Serious adverse events include tendon rupture, especially in the Achilles tendon, QT interval prolongation that can lead to torsades de pointes, severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, peripheral neuropathy, and hepatotoxicity. Prompt medical attention is required if these occur.

Moxifloxacino Kabi is contraindicated in patients with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, those with prolonged QT interval, and patients receiving concomitant drugs that significantly prolong QT.